OpenSourceMalaria:GSK Amino-thienopyrimidine Series

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
(GSK Thienopyrimidine Series)
(GSK Thienopyrimidine Series)
Line 2: Line 2:
==GSK Thienopyrimidine Series==
==GSK Thienopyrimidine Series==
 +
 +
===Preamble===
 +
 +
This page describes the current status of one of three antimalarial drug candidates being investigated by the [http://www.chem.usyd.edu.au/research/todd.html Todd laboratory] at the University of Sydney, using a strictly open source approach. A more thorough discussion of this approach may be found at: [[OSDDMalaria:Story so far]].
 +
 +
The drug development being performed in this project is open source. Such an approach involves adherance to the six laws of open source science.
 +
 +
1)  First law: All data are open and all ideas are shared
 +
2)  Second Law: Anyone can take part at any level of the project
 +
3)  Third Law: There will be no patents
 +
4)  Fourth Law: Suggestions are the best form of criticism
 +
5)  Fifth Law: Public discussion is much more valuable than private email
 +
6)  Sixth Law: The project is bigger than, and is not owned by, any given lab. The aim is to find a good drug for malaria, by whatever means, as quickly as possible.
 +
 +
All experimental work in this project is described on an [http://malaria.ourexperiment.org/aminotpseries open lab book]; status updates for the project are posted on [http://www.thesynapticleap.org/node/343 the synaptic leap]; and some discussions take place on [https://plus.google.com/u/0/114702323662314783325/posts Google+] and [http://twitter.com/osddmalaria Twitter] where convinient. All are publicly viewable and, once a member of the relevant platforms (eg: Facebook), anyone may discuss the project in the open. '''All discussion, suggestions, complaints and queries are welcome'''.
The first structure in this series, [https://www.ebi.ac.uk/chemblntd/compound/results/9372/1/molweight/asc/mini | TCMDC 135294], has the following structure:
The first structure in this series, [https://www.ebi.ac.uk/chemblntd/compound/results/9372/1/molweight/asc/mini | TCMDC 135294], has the following structure:

Revision as of 01:30, 21 November 2012

Malaria Home        OSM So Far        Compound Series        Links        Open Source Research Home        Technical Operations       


Contents

GSK Thienopyrimidine Series

Preamble

This page describes the current status of one of three antimalarial drug candidates being investigated by the Todd laboratory at the University of Sydney, using a strictly open source approach. A more thorough discussion of this approach may be found at: OSDDMalaria:Story so far.

The drug development being performed in this project is open source. Such an approach involves adherance to the six laws of open source science.

1) First law: All data are open and all ideas are shared 2) Second Law: Anyone can take part at any level of the project 3) Third Law: There will be no patents 4) Fourth Law: Suggestions are the best form of criticism 5) Fifth Law: Public discussion is much more valuable than private email 6) Sixth Law: The project is bigger than, and is not owned by, any given lab. The aim is to find a good drug for malaria, by whatever means, as quickly as possible.

All experimental work in this project is described on an open lab book; status updates for the project are posted on the synaptic leap; and some discussions take place on Google+ and Twitter where convinient. All are publicly viewable and, once a member of the relevant platforms (eg: Facebook), anyone may discuss the project in the open. All discussion, suggestions, complaints and queries are welcome.

The first structure in this series, | TCMDC 135294, has the following structure:

GSK Thienopyrimidine Series: TCMDC 135294
GSK Thienopyrimidine Series: TCMDC 135294

| ChEMBL 581088 link.

| ChemSpider link.

SMILES: Nc1ncnc2cc(sc12)c3cccc(c3)S(=O)(=O)N

PubChem: [1]

InChI=1S/C12H10N4O2S2/c13-12-11-9(15-6-16-12)5-10(19-11)7-2-1-3-8(4-7)20(14,17)18/h1-6H,(H2,13,15,16)(H2,14,17,18)

Of all structures on the GSKTCAMS that have the aminothienopyrimidine moiety, this molecule has the most attractive ALogP value and the lowest molecular weight (search performed by Jim Cronshaw 5/8/12 on ChemblNTD). We therefore argue that this compound is an excellent starting point for a lead development campaign, pending confirmation of the compound's antimalarial activity. This compound must be synthesised anew and fully characterised before submitting it for an in vitro screen against the parasite. If the compound displays potent antimalarial activity then a lead development campaign will begin.

Synthesis

The proposed synthesis for this compound is below:

Proposed synthesis for the above compound
Proposed synthesis for the above compound

Alternatives

The step that involves n-BuLi would best be avoided, and if a more direct route of arriving at the Suzuki coupling step could be discovered, that would take a potentially dangerous and difficult step out of the synthetic route.

One possibility, involving NIS and an ionic liquid such as 1-Butyl-3-methylimidazolium tetrafluoroborate (which our lab doesn't have, but which is available from Aldrich in catalytic quality from $247/5g), is found below:

[doi:10.1016/j.tetlet.2011.03.010 DOI]

[dx.doi.org/10.1139/V09-125 Here] is another alternative, where the direct iodonation of arenes can be carried out using oxone and NaI. Whether or not this would work in my compound, given selectivity issues, is something that I'll have to investigate.

This paper shows a method of direct halogenation of thiophenes. This uses [Bis(trifluoroacetoxy)iodo]benzene, which we don't have lying around, but which can be bought from Aldrich for $136/10g. The reactivity of thiophenes vs pyrimidines is something I'll have to look into. UPDATE: I've read Clayden et al. (2012, p 727) and I'm informed that pyridine is, generally speaking, terrible at electrophilic aromatic substitution reactions. My understanding is that pyrimidine has the same reactivity as does pyridine, so there shouldn't be any selectivity problems with any of these reactions (a result that was perhaps anticipated by the BuLi reaction proceeding at the alpha position on the thiophene ring in the first place).

--- July 9th.

The BuLi reactions have literature precedent. Heffron (2010) acheives a very similar reaction, albeit with protection of a pyrimidine position (which doesn't seem to be reacting in my case anyway). Snegaroff (2009) uses (TMP)3CdLi to acheive the metallation/iodination. This less harsh base can be used at rt. This author discovered the reagent, so they are probably interested in self promotion. In any case, there is precedent for the lithium metallation proceeding.

--- July 18th

A post on ChemForums suggested that the sulfur might react with the iodine. According to Joule & Mills (p. 234) this won't happen. "The five membered heterocycles do not react with electrophiles at the heteroatom." and "...in pyrrole, electrophilic addition at the nitroge would lead to a substantial loss of resonance stabilisation - the molecule would be converted into a cyclic butadiene, with an attached nitrogen carrying a positive charge localised on that nitrogen atom.

--- August 26

A search performed on SciFinder at 8:57pm revealed that the meta sulfonamide is NOT novel.

Thiophene Starting Material Synthesis

Additionally, the thiophene available from Sigma Aldrich for $159/10g can be made from the following synthesis.

Proposed synthesis for the above compound
Proposed synthesis for the above compound

Analogues

TCMDC 135294 is part of a series with one other member, | TCMDC 135255, shown below:

TCMDC 135255
TCMDC 135255

| ChEMBL639249 link.

| ChemSpider link.

SMILES: Nc1ncnc2cc(sc12)c3cccc(NC(=O)Nc4ccccc4)c3

InChI=1S/C19H15N5OS/c20-18-17-15(21-11-22-18)10-16(26-17)12-5-4-8-14(9-12)24-19(25)23-13-6-2-1-3-7-13/h1-11H,(H2,20,21,22)(H2,23,24,25)

A list of commercially available compounds with similar structures to the one I'm trying to synthesise were identified with much help from Iain Wallace. If you're reading this and are interested in donating samples of these compounds, feel free to contact me: Jim Cronshaw

Iain Wallace created a cytoscape file which details purchaseable compounds related to the two series that I am trying to make. The file can be found here, and Cytoscape can be downloaded for free here (one will need to activate the chemviz plugin, which can be activated from within Cytoscape). The results of this work, in the form of a list of purchaseable compounds, can be found here

A list of the above compounds in .csv format, with InChi, InChiKey, SMILES and eMolecules identifiers, can be found here.

These compounds, and relevant data, are shown below:

OLD DATA NOW IRRELEVANT. REFER TO NEW DATA BELOW:

Two compounds have since become unavailable from Enamine. These are commercially available but with a less strict similarity search on emolecules. http://www.emolecules.com/cgi-bin/rene/visitor.cgi?h=c22c97319d83c434da71f7f53149d7d2aaf0fe3014125ab4

Image:NewThienosFromEnamineR.png Image:NewThienosFromEnamine1R.png

Synthesis of new analogues

This image presents some strategies for assessing SAR's on the aminothienopyrimidine core.

Image:Variability.png

References

| Barker, J. M.; Huddleston, P. R.; Wood, M. L., A RAPID CONVERSION OF 3-OXOTHIOLANES INTO 3-AMINOTHIOPHENES. Synthetic Communications 2002, 32 (16), 2565-2568.

| Baykal, A. T.; Kakalis, L.; Jordan, F., Electronic and nuclear magnetic resonance spectroscopic features of the 1 ',4 '-iminopyrimidine tautomeric form of thiamin diphosphate, a novel intermediate on enzymes requiring this coenzyme. Biochemistry 2006, 45 (24), 7522-7528.

Brown, G. B.; Baker, B. R.; Bernstein, S.; Safir, S. R., BIOTIN. II. 3,4-trans-DIAMINOTHIOPHANE. The Journal of Organic Chemistry 1947, 12 (1), 155-159.

Castenado, G.; Dotson, J.; Goldsmith, R.; Gunzo, J.; Heffron, T.; Mathieu, S.; Oliveo, A.; Staben, S.; Sutherlin, D.P.; Tsui, V.; Wang, S.; Zhu, B.; Bayliss, T.; Chuckowree, I.; Folkes, A.; Wan, N.C. (Genentech, Inc., USA; Piramed Limited). Thienopyrimidine and furopyrimidine derivatives as phosphoinositide 3-kinase inhibitor and their preparation, pharmaceutical compositions and use in the treatment of cancer. World Intellectual Property Organisation 2008073785 A2, 2008; SciFinder Scholar AN 2008:735944 (accessed 2/2/2012).

| Diel, B. N.; Han, M. C.; Kole, P. L.; Boaz, D. B., Synthesis of (C-13(6)-Ring-(U))-(+/-)-benzo(a)pyrene metabolites from (C-13(6)-Ring-(U))benzene. Journal of Labelled Compounds & Radiopharmaceuticals 2007, 50 (5-6), 551-553.

| F, Duus., A study of the tautomerism of 2- and 4-ethoxycarbonylthiolan-3-ones implicating stereochemical effects of ring-substitution. Tetrahedron 1981, 37 (15), 2633-2640.

Son, J.B.; Jung, S. H.; Choi, W.I.; Jung, Y.H.; Choi, J.Y.; Song, J.Y.; Lee, K.H.; Lee, J.C.; Kim, E.Y.; Ahn, Y.G.; Kim, M.S.; Choi, HG.; Sim, T.B.; Ham, Y.J.; Park, D.; Kim, H.; Kim, D. (Hanmi Holdings Co., Ltd., S. Korea; Korea Institute of Science and Technology; Catholic University Industry Academic Cooperation Foundation). Preparation of thienopyrimidine derivatives for use as protein kinase inhibitors. World Intellectual Property Organisation 2011093684 A2, 2011; SciFinder Scholar AN 2011:971406 (accessed 3/2/2012).

Woodward, R. B.; Eastman, R. H., Tetrahydrothiophene ("Thiophane") Derivatives. J. Am. Chem. Soc. 1946, 68 (11), 2229-2235.

Personal tools